Clinical application value of MYO1-G methylation in plasma circulating tumor DNA combined with fecal occult blood test for early screening of colorectal cancer.
{"title":"Clinical application value of MYO1-G methylation in plasma circulating tumor DNA combined with fecal occult blood test for early screening of colorectal cancer.","authors":"Di Kang, Jing Li, Jingquan Xu, Yangyang Li, Weiliang Song, Zili Zhang","doi":"10.1016/j.clinre.2025.102690","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Multiple screening strategies are guideline-endorsed for colorectal cancer (CRC). We investigated the clinical value of plasma circulating tumor DNA (ctDNA) MYO1-G methylation and fecal occult blood test (FOBT) combination in CRC screening.</p><p><strong>Methods: </strong>Participants were allocated to the healthy control, colorectal polyp (Col-pol), and CRC groups. Blood and stool samples were collected at least 1 day before colonoscopy, and plasma ctDNA MYO1-G methylation was measured. The quantitative FOBT was conducted using a fully-automatic OC-Sensor analyzer. CRC patients were assigned to the high-methylation (n = 34) and low-methylation (n = 33) groups as per the median value of methylation ratio of ctDNA MYO1-G. The diagnostic value of plasma ctDNA MYO1-G methylation plus FOBT and the correlation between sensitivity and clinical variables were analyzed.</p><p><strong>Results: </strong>Col-pol or CRC patients exhibited raised plasma ctDNA MYO1-G methylation copy number and methylation ratio, with CRC patients showing a higher ratio. There was no significant difference in the total copy number of MYO1-G among the three groups. Plasma ctDNA MYO1-G methylation plus FOBT could distinguish Col-pol (AUC = 0.823) and CRC (AUC = 0.955) patients from controls, and discriminate CRC from Col-pol (AUC = 0.844), displaying higher performance than FOBT. The sensitivity of their combination for assessing CRC was independent of gender, age, tumor size, clinical TNM stage, differentiation degree, pathological pattern, and histology, whereas FOBT sensitivity varied by age (p = 0.04), with higher sensitivity in CRC patients >50 years old.</p><p><strong>Conclusion: </strong>Plasma ctDNA MYO1-G methylation plus FOBT exhibits high diagnostic value for Col-pol/CRC.</p>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":" ","pages":"102690"},"PeriodicalIF":2.4000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinics and research in hepatology and gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clinre.2025.102690","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Multiple screening strategies are guideline-endorsed for colorectal cancer (CRC). We investigated the clinical value of plasma circulating tumor DNA (ctDNA) MYO1-G methylation and fecal occult blood test (FOBT) combination in CRC screening.
Methods: Participants were allocated to the healthy control, colorectal polyp (Col-pol), and CRC groups. Blood and stool samples were collected at least 1 day before colonoscopy, and plasma ctDNA MYO1-G methylation was measured. The quantitative FOBT was conducted using a fully-automatic OC-Sensor analyzer. CRC patients were assigned to the high-methylation (n = 34) and low-methylation (n = 33) groups as per the median value of methylation ratio of ctDNA MYO1-G. The diagnostic value of plasma ctDNA MYO1-G methylation plus FOBT and the correlation between sensitivity and clinical variables were analyzed.
Results: Col-pol or CRC patients exhibited raised plasma ctDNA MYO1-G methylation copy number and methylation ratio, with CRC patients showing a higher ratio. There was no significant difference in the total copy number of MYO1-G among the three groups. Plasma ctDNA MYO1-G methylation plus FOBT could distinguish Col-pol (AUC = 0.823) and CRC (AUC = 0.955) patients from controls, and discriminate CRC from Col-pol (AUC = 0.844), displaying higher performance than FOBT. The sensitivity of their combination for assessing CRC was independent of gender, age, tumor size, clinical TNM stage, differentiation degree, pathological pattern, and histology, whereas FOBT sensitivity varied by age (p = 0.04), with higher sensitivity in CRC patients >50 years old.
Conclusion: Plasma ctDNA MYO1-G methylation plus FOBT exhibits high diagnostic value for Col-pol/CRC.
期刊介绍：
Clinics and Research in Hepatology and Gastroenterology publishes high-quality original research papers in the field of hepatology and gastroenterology. The editors put the accent on rapid communication of new research and clinical developments and so called "hot topic" issues. Following a clear Editorial line, besides original articles and case reports, each issue features editorials, commentaries and reviews. The journal encourages research and discussion between all those involved in the specialty on an international level. All articles are peer reviewed by international experts, the articles in press are online and indexed in the international databases (Current Contents, Pubmed, Scopus, Science Direct).
Clinics and Research in Hepatology and Gastroenterology is a subscription journal (with optional open access), which allows you to publish your research without any cost to you (unless you proactively chose the open access option). Your article will be available to all researchers around the globe whose institution has a subscription to the journal.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
